Potential of medicinal mushroom extracts as adjunctive agents to enhance conversion therapy in colorectal cancer with liver and peritoneal metastases

Abstract

Colorectal cancer (CRC) with liver metastases (LM) and peritoneal metastases (PM) presents a formidable challenge with poor prognosis despite advances in systemic chemotherapy and combined surgical approaches, including cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Median overall survival (OS) for such unresectable cases ranges from 12 to 24 months with modern regimens (e.g., 5-fluorouracil [5-FU], leucovorin, and oxaliplatin/5-FU, leucovorin, and irinotecan + targeted therapies). However, conversion to resectable diseases remains limited by disease extent and treatment toxicity. This paper proposes that medicinal mushroom extracts, particularly polysaccharides (e.g., polysaccharide krestin and polysaccharopeptide) from Trametes versicolor and bioactive compounds from species, such as Ganoderma lucidum, could enhance conversion therapy outcomes in CRC with LM and PM. Evidence from pre-clinical and clinical studies demonstrates that these extracts exert anticancer effects through multiple mechanisms, including suppression of multidrug resistance, blockade of immune checkpoints (e.g., programmed cell death protein 1/programmed death-ligand 1), regulation of oncogenic signaling pathways (e.g., phosphoinositide 3-kinase/protein kinase B, mitogen-activated protein kinase, and Nuclear factor kappa-light-chain-enhancer of activated B cells), and robust immunomodulation. Meta-analyses of over 8,000 patients reported improved survival and tolerability when combining the extracts with chemotherapy post-surgery. Similarly, meta-analysis in the present study, involving 2,397 patients, reveals a 10% relative increase in the probability of survival at 5 years, with a survival risk ratio of 1.10 (95% confidence interval: 1.04-1.15), based on post-operative data without direct pre-operative validation. Integrating these extracts into neoadjuvant regimens could enhance chemotherapy efficacy, increase surgical eligibility, and mitigate toxicity, potentially extending OS. While direct evidence in unresectable CRC with dual metastases is lacking, the biological plausibility and safety profile of mushroom extracts warrant prospective trials to validate their role in conversion therapy.

Keywords

Colorectal cancer / Liver metastases / Peritoneal metastases / Conversion therapy / Medicinal mushrooms / Trametes versicolor / Ganoderma lucidum / Immunomodulation

References

[1] Kim YJ, Kim CH. Treatment for peritoneal metastasis of patients with colorectal cancer. Ann Coloproctol. 2021; 37(6):425-433. doi: 10.3393/ac.2021.00920.0131

[2] Kow AWC.Hepatic metastasis from colorectal cancer. J Gastrointest Oncol. 2019; 10(6):1274-1298. doi: 10.21037/jgo.2019.08.06

[3] März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep (Oxf). 2015; 3(4):298-302. doi: 10.1093/gastro/gov044

[4] Klaver YLB, Simkens LHJ, Lemmens VEPP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012; 38(7):617-623. doi: 10.1016/j.ejso.2012.03.008

[5] Nadler A, McCart JA, Govindarajan A. Peritoneal carcinomatosis from colon cancer: A systematic review of the data for cytoreduction and intraperitoneal chemotherapy. Clin Colon Rectal Surg. 2015; 28(4):234-246. doi: 10.1055/s-0035-1564431

[6] Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016; 17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9

[7] Mendoza-Moreno F, Diez-Alonso M, Matías-García B, et al. Prognostic factors of survival in patients with peritoneal metastasis from colorectal cancer. J Clin Med. 2022; 11(16):4922. doi: 10.3390/jcm11164922

[8] Franko J. Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: Surgeon’s perspective. Pleura Peritoneum. 2018; 3(1):20180102. doi: 10.1515/pp-2018-0102

[9] Cohen R, Raeisi M, Chibaudel B, et al. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis. Eur J Cancer. 2024; 207:114160. doi: 10.1016/j.ejca.2024.114160

[10] Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014; 371(17):1609-1618. doi: 10.1056/NEJMoa1403108

[11] Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020; 38(28): 3314-3324. doi: 10.1200/JCO.20.01225

[12] Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023; 41(3):678-700. doi: 10.1200/JCO.22.01690

[13] Polderdijk MCE, Brouwer M, Haverkamp L, et al. Outcomes of combined peritoneal and local treatment for patients with peritoneal and limited liver metastases of colorectal origin: A systematic review and meta-analysis. Ann Surg Oncol. 2022; 29(3):1952-1962. doi: 10.1245/s10434-021-10925-y

[14] Lo Dico R, Faron M, Yonemura Y, et al. Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021; 47(1):89-100. doi: 10.1016/j.ejso.2020.07.038

[15] Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: A systematic review and pooled analysis. JAMA Oncol. 2017; 3(7):e170278. doi: 10.1001/jamaoncol.2017.0278

[16] Mo S, Cai G. Multidisciplinary treatment for colorectal peritoneal metastases: Review of the literature. Gastroenterol Res Pract. 2016; 2016(1): 1516259. doi: 10.1155/2016/1516259

[17] Rodriguez-Bigas MA, Lin EH, Crane CH.Stage IV colorectal cancer. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th ed. Hamilton, ON: BC Decker; 2003. Available from: https://www.ncbi.nlm.nih.gov/books/NBK13267 [Last accessed on 2025 Aug 13].

[18] Ghiasloo M, Pavlenko D, Verhaeghe M, et al. Surgical treatment of stage IV colorectal cancer with synchronous liver metastases: A systematic review and network meta-analysis. Eur J Surg Oncol. 2020; 46(7):1203-1213. doi: 10.1016/j.ejso.2020.02.040

[19] Ströhlein MA, Heiss MM. Limitations of the PRODIGE 7 trial. Lancet Oncol. 2021; 22(5):e178. doi: 10.1016/S1470- 2045(21)00134-0

[20] van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018; 378(3):230-240. doi: 10.1056/NEJMoa1708618

[21] Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21(20):3737-3743. doi: 10.1200/JCO.2003.04.187

[22] Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia withoxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009; 27(5):681-685. doi: 10.1200/JCO.2008.19.7160

[23] Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010; 116(16):3756-3762. doi: 10.1002/cncr.25116

[24] Cashin PH, Mahteme H, Spång N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. Eur J Cancer. 2016; 53:155-162. doi: 10.1016/j.ejca.2015.09.017

[25] Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4

[26] Goéré D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study. Lancet Oncol. 2020; 21(9):1147-1154. doi: 10.1016/S1470-2045(20)30322-3

[27] Sugarbaker PH, Van der Speeten K. The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. J Gastrointest Oncol. 2021; 12(Suppl 1):S129-S130. doi: 10.21037/jgo-2020-15

[28] Cashin P, Sugarbaker PH. Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7. J Gastrointest Oncol. 2021; 12(Suppl 1):S120-S128. doi: 10.21037/jgo-2020-05

[29] Pereira F, Serrano A, Manzanedo I, et al. GECOP-MMC: Phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer. 2022; 22(1):536. doi: 10.1186/s12885-022-09572-7

[30] Park HJ. Current uses of mushrooms in cancer treatment and their anticancer mechanisms. Int J Mol Sci. 2022; 23(18):10502. doi: 10.3390/ijms231810502

[31] Sadava D, Still DW, Mudry RR, Kane SE. Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Lett. 2009; 277(2):182-189. doi: 10.1016/j.canlet.2008.12.009

[32] Sohretoglu D, Huang S. Ganoderma lucidum polysaccharides as an anti-cancer agent. Anticancer Agents Med Chem. 2018; 18(5):667-674. doi: 10.2174/1871520617666171113121246

[33] Margret AA, Mareeswari R, Kumar KA, Jerley AA. Relative profiling of L-tryptophan derivatives from selected edible mushrooms as psychoactive nutraceuticals to inhibit P-glycoprotein: A paradigm to contest blood-brain barrier. BioTechnologia (Pozn). 2021; 102(1):55-64. doi: 10.5114/bta.2021.103762

[34] Zhong X, Wang G, Li F, et al. Immunomodulatory effect and biological significance of β-glucans. Pharmaceutics. 2023; 15(6):1615. doi: 10.3390/pharmaceutics15061615

[35] Wang M, Bai Y, Pei J, et al. β-Glucan combined with PD-1/ PD-L1 checkpoint blockade for immunotherapy in patients with advanced cancer. Front Pharmacol. 2022; 13:887457. doi: 10.3389/fphar.2022.887457

[36] André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020; 383(23):2207-2218. doi: 10.1056/NEJMoa2017699

[37] Wang G, Wang L, Zhou J, Xu X. The possible role of PD-1 protein in Ganoderma lucidum-mediated immunomodulation and cancer treatment. Integr Cancer Ther. 2019; 18:1534735419880275. doi: 10.1177/1534735419880275

[38] Jian L, Zhicheng H, Shubai L. Polysaccharide peptide induced colorectal cancer cells apoptosis by down-regulating EGFR and PD-L1 expression. Iran J Pharm Res. 2022; 21(1):e123909. doi: 10.5812/ijpr-123909

[39] Kim TI, Choi JG, Kim JH, Li W, Chung HS. Blocking effect of Chaga mushroom (Inonotus obliquus) extract for immune checkpoint CTLA-4/CD 80 interaction. Appl Sci. 2020; 10(17):5774. doi: 10.3390/app10175774

[40] Randeni N, Xu B. New insights into signaling pathways of cancer prevention effects of polysaccharides from edible and medicinal mushrooms. Phytomedicine. 2024; 132:155875. doi: 10.1016/j.phymed.2024.155875

[41] Cheng Y, Xie P. Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K/AKT signaling pathway. J Biochem Mol Toxicol. 2019; 33(11):e22392. doi: 10.1002/jbt.22392

[42] Joseph TP, Chanda W, Padhiar AA, et al. A preclinical evaluation of the antitumor activities of edible and medicinal mushrooms: A molecular insight. Integr Cancer Ther. 2018; 17(2):200-209. doi: 10.1177/1534735417736861

[43] Kang JH, Jang JE, Mishra SK, et al. Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the β-catenin pathway in colorectal cancer. J Ethnopharmacol. 2015; 173:303-312. doi: 10.1016/j.jep.2015.07.030

[44] Ina H, Yoneda M, Kanda M, et al. Lentinan, a shiitake mushroom β-glucan, stimulates tumor-specific adaptive immunity through PD-L1 down-regulation in gastric cancer cells. Med Chem. 2016; 6(12):1000419. doi: 10.4172/2161-0444.1000419

[45] Thyagarajan A, Jedinak A, Nguyen H, et al. Triterpenes from Ganoderma lucidum induce autophagy in colon cancer through the inhibition of p 38 mitogen-activated kinase (p38 MAPK). Nutr Cancer. 2010; 62(5):630-640. doi: 10.1080/01635580903532390

[46] Yang CLH, Chik SCC, Lau ASY, Chan GCF. Coriolus versicolor and its bioactive molecule are potential immunomodulators against cancer cell metastasis via inactivation of MAPK pathway. J Ethnopharmacol. 2023; 301:115790. doi: 10.1016/j.jep.2022.115790

[47] Wang CL, Meng M, Liu SB, Wang LR, Hou LH, Cao XH. A chemically sulfated polysaccharide from Grifola frondosa induces HepG2 cell apoptosis by Notch1-NF-κB pathway. Carbohydr Polym. 2013; 95(1):282-287. doi: 10.1016/j.carbpol.2013.02.057

[48] Gao Y, Dai X, Chen G, Ye J, Zhou S. A randomized, placebo-controlled, multicenter study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) polysaccharides (Ganopoly®) in patients with advanced lung cancer. Int J Med Mushrooms. 2003; 5(4):14. doi: 10.1615/InterJMedicMush.v5.i4.40

[49] Zhao H, Zhang Q, Zhao L, Huang X, Wang J, Kang X. Spore powder of Ganoderma lucidum improves cancer-related fatigue in breast cancer patients undergoing endocrine therapy: A pilot clinical trial. Evid Based Complement Alternat Med. 2012; 2012(1): 809614. doi: 10.1155/2012/809614

[50] Deng G, Lin H, Seidman A, et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: Immunological effects. J Cancer Res Clin Oncol. 2009; 135(9):1215-1221. doi: 10.1007/s00432-009-0562-z

[51] Israilides C, Kletsas D, Arapoglou D, et al. In vitro cytostatic and immunomodulatory properties of the medicinal mushroom Lentinula edodes. Phytomedicine. 2008; 15(6-7): 512-519. doi: 10.1016/j.phymed.2007.11.029

[52] Wasser SP, Weis AL. Medicinal properties of substances occurring in higher Basidiomycetes mushrooms: Current perspectives (review). Int J Med Mushrooms. 1999; 1(1):31-62. doi: 10.1615/IntJMedMushrooms.v1.i1.30

[53] Ahn WS, Kim DJ, Chae GT, et al. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer. 2004; 14(4):589-594. doi: 10.1136/ijgc-00009577-200407000-00003

[54] Hetland G, Tangen JM, Mahmood F, et al. Antitumor, anti-inflammatory and antiallergic effects of Agaricus blazei mushroom extract and the related medicinal basidiomycetes mushrooms, Hericium erinaceus and Grifola frondosa: A review of preclinical and clinical studies. Nutrients. 2020; 12(5):1339. doi: 10.3390/nu12051339

[55] Saleh MH, Rashedi I, Keating A. Immunomodulatory properties of Coriolus versicolor: The role of polysaccharopeptide. Front Immunol. 2017; 8:1087. doi: 10.3389/fimmu.2017.01087

[56] Lee CL, Yang X, Wan JMF. The culture duration affects the immunomodulatory and anticancer effect of polysaccharopeptide derived from Coriolus versicolor. Enzyme Microb Technol. 2006; 38(1-2):14-21. doi: 10.1016/j.enzmictec.2004.10.009

[57] Mao XW, Archambeau JO, Gridley DS. Immunotherapy with low-dose interleukin-2 and a polysaccharopeptide derived from Coriolus versicolor. Cancer Biother Radiopharm. 1996; 11(6):393-403. doi: 10.1089/cbr.1996.11.393

[58] Jędrzejewski T, Sobocińska J, Pawlikowska M, Dzialuk A, Wrotek S. Extract from the Coriolus versicolor fungus as an anti-inflammatory agent with cytotoxic properties against endothelial cells and breast cancer cells. Int J Mol Sci. 2020; 21(23):9063. doi: 10.3390/ijms21239063

[59] Akagi J, Baba H. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients. Int J Clin Oncol. 2010; 15(2):145-152. doi: 10.1007/s10147-010-0033-1

[60] Sadahiro S, Suzuki T, Maeda Y, et al. Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma. Anticancer Res. 2010; 30(3):993-999.

[61] Hui KPY, Sit WH, Wan JMF. Induction of S phase cell arrest and caspase activation by polysaccharide peptide isolated from Coriolus versicolor enhanced the cell cycle dependent activity and apoptotic cell death of doxorubicin and etoposide, but not cytarabine in HL-60 cells. Oncol Rep. 2005; 14(1):145-155. doi: 10.3892/or.14.1.145

[62] Coriolus versicolor. Purported Benefits, Side Effects & More. Memorial Sloan Kettering Cancer Center.Available from: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/coriolus-versicolor [Last accessed on 2025 Aug 13].

[63] Jiang J, Sliva D. Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells. Int J Oncol. 2010; 37(6):1529-1536. doi: 10.3892/ijo_00000806

[64] Habtemariam S. Trametes versicolor (synn. Coriolus versicolor) polysaccharides in cancer therapy: Targets and efficacy. Biomedicines. 2020; 8(5):135. doi: 10.3390/biomedicines8050135

[65] Hsieh TC, Wu P, Park S, Wu JM. Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I’m-Yunity (PSP). BMC Complement Altern Med. 2006; 6:30. doi: 10.1186/1472-6882-6-30

[66] Jędrzejewski T, Pawlikowska M, Sobocińska J, Wrotek S. Protein-bound polysaccharides from Coriolus versicolor fungus disrupt the crosstalk between breast cancer cells and macrophages through inhibition of angiogenic cytokines production and shifting tumour-associated macrophages from the M2 to M1 subtype. Cell Physiol Biochem. 2020; 54(4):615-628. doi: 10.33594/000000244

[67] Ho JCK, Konerding MA, Gaumann A, Groth M, Liu WK. Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice. Life Sci. 2004; 75(11):1343-1356. doi: 10.1016/j.lfs.2004.02.021

[68] Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: An overview. Cancer Epidemiol Biomarkers Prev. 1995; 4(3):275-281.

[69] Takahashi M, Hizuta M, Suo J, et al. Antitumor effect of oral administration of PSK in tumor-bearing mice and rats. Biotherapy (Tokyo). 1992; 6(5):766-768. doi: 10.1002/(sici)1097-0215(19970127)70:3<362:aid-ijc19>3.0.co;2-h

[70] Suo J, Yunoki S, Murakami H, et al. Anticancer effect of oral administration of UFT and PSK in murine hepatic metastasis model. Biotherapy (Tokyo). 1990; 4(3):766-780.

[71] Luo KW, Yue GGL, Ko CH, et al. In vivo and in vitro anti-tumor and anti-metastasis effects of Coriolus versicolor aqueous extract on mouse mammary 4T 1 carcinoma. Phytomedicine. 2014; 21(8-9):1078-1087. doi: 10.1016/j.phymed.2014.04.020

[72] Yoshikawa R, Yanagi H, Noda M, Yamamura T, Hashimoto-Tamaoki T. Polysaccharide-K (PSK) inhibits distant metastasis in colorectal cancer dependent on ECA39. Cancer Res. 2005; 65(9 Suppl):171.

[73] Zhong L, Yan P, Lam WC, Yao L, Bian Z. Coriolus versicolor and Ganoderma lucidum related natural products as an adjunct therapy for cancers: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2019; 10:703. doi: 10.3389/fphar.2019.00703

[74] Mycomedicinals (Mushrooms) for Cancer. U.S. Department of Veterans Affairs.Available from: https://www.va.gov/wholehealthlibrary/tools/mycomedicinals-mushrooms-for-cancer.asp [Last accessed on 2025 Aug 13].

[75] Medicinal Mushrooms (PDQ®)-Health Professional Version. National Cancer Institute. Last accessed on 2025 Aug 13].

[76] Cizmarikova M. The efficacy and toxicity of using the Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum (Agaricomycetes), and its products in chemotherapy (review). Int J Med Mushrooms. 2017; 19(10):861-877. doi: 10.1615/intjmedmushrooms.2017024537

[77] Jin X, Beguerie JR, Sze DMY, Chan GCF. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2012;6:CD007731. doi: 10.1002/14651858.CD007731.pub2

[78] Jin X, Beguerie JR, Sze DMY, Chan GCF. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016; 4(4):CD007731. doi: 10.1002/14651858.CD007731.pub3

[79] Phase II Clinical Trial Scheme of Ganoderma lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma.Available from: https://clinicaltrials.gov/study/NCT04319874 [Last accessed on 2025 Aug 13].

[80] Oka S, Tanaka S, Yoshida S, et al. A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci. 2010; 59(1):1-6.

[81] Zhang Y, Jiang Y, Zhang M, Zhang L. Ganoderma sinense polysaccharide: An adjunctive drug used for cancer treatment. Prog Mol Biol Transl Sci. 2019; 163:165-177. doi: 10.1016/bs.pmbts.2019.02.008

[82] Konno S. Synergistic potentiation of D-fraction with vitamin C as possible alternative approach for cancer therapy. Int J Gen Med. 2009; 2:91-108. doi: 10.2147/ijgm.s5498

[83] Nanba H. Maitake D-fraction: Healing and preventive potential for cancer. J Orthomol Med. 1997; 12(1):43-49.

[84] Kodama N, Komuta K, Nanba H. Can Maitake MD-fraction aid cancer patients? Altern Med Rev. 2002; 7(3):236-239.

[85] Zhang M, Zhang Y, Zhang L, Tian Q. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Prog Mol Biol Transl Sci. 2019; 163:297-328. doi: 10.1016/bs.pmbts.2019.02.013

[86] Cheetham P, Lifton D. The Patient’s Guide to AHCC Active Hexose Correlated Compound. The Clinically Proven Nutrient Supported by 25 Clinical Studies. United States: Woodland Publishing; 2012.

[87] Cowawintaweewat S, Manoromana S, Sriplung H, et al. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol. 2006; 24(1):33-45.

[88] Ghoneum M, Wimbley M, Salem F, Mcklain A, Attallah N, Gill G. Immunomodulatory and anticancer effects of active hemicellulose compound (AHCC). Int J Immunother. 1995; 11(1):23-28.

[89] Matsui Y, Uhara J, Satoi S, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: A prospective cohort study. J Hepatol. 2002; 37(1):78-86. doi: 10.1016/S0168-8278(02)00091-0

[90] He Z, Lin J, He Y, Liu S. Polysaccharide-peptide from Trametes versicolor: The potential medicine for colorectal cancer treatment. Biomedicines. 2022; 10(11):2841. doi: 10.3390/biomedicines10112841

[91] Chang Y, Zhang M, Jiang Y, et al. Preclinical and clinical studies of Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Discov Med. 2017; 23(127):207-219.

[92] Eliza WLY, Fai CK, Chung LP. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: Systematic review and meta-analysis. Recent Pat Inflamm Allergy Drug Discov. 2012; 6(1):78-87. doi: 10.2174/187221312798889310

[93] Fritz H, Kennedy DA, Ishii M, et al. Polysaccharide K and Coriolus versicolor extracts for lung cancer: A systematic review. Integr Cancer Ther. 2015; 14(3):201-211. doi: 10.1177/1534735415572883

[94] Pilkington K, Wieland LS, Teng L, Jin XY, Storey D, Liu JP. Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Cochrane Database Syst Rev. 2022;(11): CD012053. doi: 10.1002/14651858.CD012053.pub2

[95] Introduction to GRADE (Grading of Recommendations Assessment, Development and Evaluation). Cochrane Training. Available from: https://training.cochrane.org/introduction-grade [Last accessed on 2025 Aug 13].

[96] Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007; 56(6):905-911. doi: 10.1007/s00262-006-0248-1

[97] Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: A meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother. 2006; 55(4):404-411. doi: 10.1007/s00262-005-0054-1

[98] Yoshitani SI, Takashima S. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. Cancer Biother Radiopharm. 2009; 24(1):35-40. doi: 10.1089/cbr.2008.0547

[99] Sakai T, Yamashita Y, Maekawa T, Mikami K, Hoshino S, Shirakusa T. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm. 2008; 23(4):461-468. doi: 10.1089/cbr.2008.0484

[100] Tsang KW, Lam CL, Yan C, et al. Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Respir Med. 2003; 97(6):618-624. doi: 10.1053/rmed.2003.1490

[101] Miyake Y, Nishimura J, Kato T, et al. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG). Surg Today. 2018; 48(1):66-72. doi: 10.1007/s00595-017-1555-1

[102] Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg. 1988; 18(6):681-686. doi: 10.1007/BF02471530

[103] Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother. 1990; 31(5):261-268. doi: 10.1007/BF01740932

[104] Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum. 1992; 35(2):123-130. doi: 10.1007/BF02050666

[105] Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994; 343(8906):1122-1126. doi: 10.1016/S0140-6736(94)90233-x

[106] Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol. 1995; 18(3):216-222.

[107] Toge T, Yamaguchi Y. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep. 2000; 7(5):1157-1161. doi: 10.3892/or.7.5.1157

[108] Ito K, Nakazato H, Koike A, et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis. 2004; 19(2):157-164. doi: 10.1007/s00384-003-0532-x

[109] Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: A randomised controlled study. Br J Cancer. 2004; 90(5):1003-1010. doi: 10.1038/sj.bjc.6601619

[110] Shichinohe T, Komatsu Y, Akazawa K, et al. Randomized phase III clinical study comparing postoperative UFT/ LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study. J Clin Oncol. 2013; 31(15_suppl):3638. doi: 10.1200/jco.2013.31.15_suppl.3638

[111] Ogawa H, Shiraishi T, Okada T, et al. Adjuvant chemotherapy with UFT/LV versus UFT/LV plus PSK in stage II/III colorectal cancer. Anticancer Res. 2024; 44(2):805-814. doi: 10.21873/anticanres.16872

[112] Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016; 7(1):55-79. doi: 10.1002/jrsm.1164

[113] Venturella G, Ferraro V, Cirlincione F, Gargano ML. Medicinal mushrooms: Bioactive compounds, use, and clinical trials. Int J Mol Sci. 2021; 22(2):634. doi: 10.3390/ijms22020634

[114] Łysakowska P, Sobota A, Wirkijowska A. Medicinal mushrooms: Their bioactive components, nutritional value and application in functional food production-a review. Molecules. 2023; 28(14):5393. doi: 10.3390/molecules28145393

[115] Cadar E, Negreanu-Pirjol T, Pascale C, et al. Natural bio-compounds from Ganoderma lucidum and their beneficial biological actions for anticancer application: A review. Antioxidants (Basel). 2023; 12(11):1907. doi: 10.3390/antiox12111907

[116] Ekiz E, Oz E, Abd El-Aty AM, et al. Exploring the potential medicinal benefits of Ganoderma lucidum: From metabolic disorders to coronavirus infections. Foods. 2023; 12(7):1512. doi: 10.3390/foods12071512

[117] Choong YK, Ellan K, Chen XD, Mohamad SA. Extraction and Fractionation of Polysaccharides from a Selected Mushroom Species, Ganoderma lucidum: A critical Review. Fractionation. London: IntechOpen; 2019. doi: 10.5772/intechopen.78047

[118] Tomoda M, Gonda R, Kasahara Y, Hikino H. Glycan structures of Ganoderans B and C, hypoglycemic glycans of Ganoderma lucidum fruit bodies. Phytochemistry. 1986; 25(12):2817-2820. doi: 10.1016/S0031-9422(00)83748-6

[119] Wu JY, Siu KC, Geng P. Bioactive ingredients and medicinal values of Grifola frondosa (Maitake). Foods. 2021; 10(1):95. doi: 10.3390/foods10010095

[120] Kodama N, Murata Y, Asakawa A, et al. Maitake D-fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice. Nutrition. 2005; 21(5):624-629. doi: 10.1016/j.nut.2004.09.021

[121] Zhang Y, Li S, Wang X, Zhang L, Cheung PCK. Advances in lentinan: Isolation, structure, chain conformation and bioactivities. Food Hydrocoll. 2011; 25(2):196-206. doi: 10.1016/j.foodhyd.2010.02.001

[122] Lentinan - an Overview. ScienceDirect.Available from: https://www.sciencedirect. com/topics/immunology-and-microbiology/lentinan [Last accessed on 2025 Aug 13].

[123] Fujii H, Nishioka N, Simon RR, Kaur R, Lynch B, Roberts A. Genotoxicity and subchronic toxicity evaluation of active hexose correlated compound (AHCC). Regul Toxicol Pharmacol. 2011; 59(2):237-250. doi: 10.1016/j.yrtph.2010.10.006

[124] Shin MS, Park HJ, Maeda T, Nishioka H, Fujii H, Kang I. The effects of AHCC® a standardized extract of cultured Lentinura edodes mycelia, on natural killer and T cells in health and disease: reviews on human and animal studies. J Immunol Res. 2019; 2019(1): 3758576. doi: 10.1155/2019/3758576

[125] Dou H, Chang Y, Zhang L. Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Prog Mol Biol Transl Sci. 2019; 163:361-381. doi: 10.1016/bs.pmbts.2019.03.001

[126] Zhang X, Cai Z, Mao H, Hu P, Li X. Isolation and structure elucidation of polysaccharides from fruiting bodies of mushroom Coriolus versicolor and evaluation of their immunomodulatory effects. Int J Biol Macromol. 2021; 166:1387-1395. doi: 10.1016/j.ijbiomac.2020.11.018

[127] Jing Y, Zhang S, Li M, et al. Research progress on the extraction, structure, and bioactivities of polysaccharides from Coriolus versicolor. Foods. 2022; 11(14):2126. doi: 10.3390/foods11142126

[128] Cui J, Chisti Y. Polysaccharopeptides of Coriolus versicolor: Physiological activity, uses, and production. Biotechnol Adv. 2003; 21(2):109-122. doi: 10.1016/S0734-9750(03)00002-8

[129] Abubakar AR, Haque M. Preparation of medicinal plants: Basic extraction and fractionation procedures for experimental purposes. J Pharm Bioallied Sci. 2020; 12(1):1-10. doi: 10.4103/jpbs.JPBS_175_19

[130] Arshadi N, Nouri H, Moghimi H. Increasing the production of the bioactive compounds in medicinal mushrooms: An omics perspective. Microb Cell Fact. 2023; 22(1):11. doi: 10.1186/s12934-022-02013-x

[131] Chow SC, Wang H, Shao J. Sample Size Calculations in Clinical Research. 2nd ed. United Kingdom: Chapman and Hall/CRC; 2007. doi: 10.1201/9781584889830